Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neurogene Inc. (NGNE : NSDQ)

• Company Description    Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK. Number of Employees: 107

• Price / Volume Information    Yesterday's Closing Price: $26.75 Daily Weekly Monthly 20 Day Moving Average: 244,528 shares Shares Outstanding: 14.27 (millions) Market Capitalization: $381.77 (millions) Beta: 1.63 52 Week High: $74.49 52 Week Low: $6.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.45% -13.77% 12 Week 30.42% 25.02% Year To Date 17.02% 2.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 535 W 24TH STREET 5TH FLOOR - NEW YORK,NY 10011 USA ph: 855-508-3568 fax: 778-331-4486 neurogene@argotpartners.com http://www.neurogene.com

• General Corporate Information    Officers Rachel McMinn - Chief Executive Officer Christine Mikail - President and Chief Financial Officer Robert Baffi - Director Cory Freedland - Director Sarah B. Noonberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 64135M105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/17/25 Share - Related Items Shares Outstanding: 14.27 Most Recent Split Date: 12.00 (0.25:1) Beta: 1.63 Market Capitalization: $381.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.74 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/17/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 3.67% vs. Previous Quarter: 2.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -33.33 03/31/25 - -36.16 ROA 09/30/25 - - 06/30/25 - -30.34 03/31/25 - -32.51 Current Ratio 09/30/25 - - 06/30/25 - 18.07 03/31/25 - 21.03 Quick Ratio 09/30/25 - - 06/30/25 - 18.07 03/31/25 - 21.03 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - -8,742.70 Book Value 09/30/25 - - 06/30/25 - 19.16 03/31/25 - 20.46 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.01

Powered by Zacks Investment Research ©